GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Skye Bioscience Inc (NAS:SKYE) » Definitions » Cyclically Adjusted Price-to-FCF

Skye Bioscience (Skye Bioscience) Cyclically Adjusted Price-to-FCF : (As of May. 21, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Skye Bioscience Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Skye Bioscience Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Skye Bioscience's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Skye Bioscience Cyclically Adjusted Price-to-FCF Chart

Skye Bioscience Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Skye Bioscience Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Skye Bioscience's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Skye Bioscience's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Skye Bioscience's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Skye Bioscience's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Skye Bioscience's Cyclically Adjusted Price-to-FCF falls into.



Skye Bioscience Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Skye Bioscience's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Skye Bioscience's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.168/131.7762*131.7762
=-0.168

Current CPI (Mar. 2024) = 131.7762.

Skye Bioscience Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201404 0.088 100.023 0.116
201407 0.235 100.520 0.308
201412 -13.610 99.070 -18.103
201503 -11.569 99.621 -15.303
201506 -8.738 100.684 -11.436
201509 -19.044 100.392 -24.998
201512 -15.260 99.792 -20.151
201603 -14.488 100.470 -19.002
201606 -15.185 101.688 -19.678
201609 -6.400 101.861 -8.280
201612 -10.359 101.863 -13.401
201703 -8.774 102.862 -11.240
201706 -2.377 103.349 -3.031
201709 -0.826 104.136 -1.045
201712 -17.574 104.011 -22.265
201803 -2.969 105.290 -3.716
201806 -2.031 106.317 -2.517
201809 -1.551 106.507 -1.919
201812 -1.917 105.998 -2.383
201903 -2.695 107.251 -3.311
201906 -2.123 108.070 -2.589
201909 -2.797 108.329 -3.402
201912 -2.144 108.420 -2.606
202003 -1.722 108.902 -2.084
202006 -1.404 108.767 -1.701
202009 -1.918 109.815 -2.302
202012 -1.486 109.897 -1.782
202103 -1.008 111.754 -1.189
202106 -1.103 114.631 -1.268
202109 -0.913 115.734 -1.040
202112 -1.018 117.630 -1.140
202203 -1.471 121.301 -1.598
202206 -1.464 125.017 -1.543
202209 -1.042 125.227 -1.096
202212 -1.665 125.222 -1.752
202303 -1.078 127.348 -1.115
202306 -0.513 128.729 -0.525
202309 -0.515 129.860 -0.523
202312 -0.312 129.419 -0.318
202403 -0.168 131.776 -0.168

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Skye Bioscience  (NAS:SKYE) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Skye Bioscience Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Skye Bioscience's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Skye Bioscience (Skye Bioscience) Business Description

Industry
Traded in Other Exchanges
N/A
Address
11250 El Camino Real, Suite 100, San Diego, CA, USA, 92130
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. It researches and develops and plans to commercialize cannabinoid derivatives through its own directed research efforts and through several license agreements with the University of Mississippi. The company's lead compound, SBI-100, is initially being developed to treat ocular disease.
Executives
Punit Dhillon director 5820 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
John D Diekman 10 percent owner C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Partners Vii, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Paul A. Grayson director 10578 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
5am Ventures Vii, L.p. 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kush Parmar 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Partners Ii, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Co-investors Ii Lp 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Versant Ventures Iii, Llc 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Scott M Rocklage 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Andrew J. Schwab director, 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Versant Side Fund Iii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
5am Ventures Ii Lp 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Versant Venture Capital Iii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Deborah H. Charych director 1001 17TH ST, SAN FRANCISCO CA 94107